| Name | Title | Contact Details |
|---|---|---|
Misha Hanin |
Head of Technology | Profile |
We are automotive company.
Aiwyn helps leading accounting firms automate and optimize critical revenue processes by unlocking client data from existing practice management and CRM systems with our Practice Automation platform. With Aiwyns Practice Automation platform, high-value firm executives, partners, and staff are liberated to deliver more value to clients and work at the highest end of their professional expertise. Benefits of Practice Automation to accounting firms include: - save time, bill faster - eliminate tedious back office tasks - reduce days-in-WIP and days-in-AR, - speed up client payments - smooth out cash flow - protect financial health with predictive insights and controls - offer a best-in-class experience to both employees and clients
At Mako Fire Group our main goal is helping you protect what matters most, and we take great pride in that. Our companies highly qualified technicians undergo a rigorous training surpassing what is required of them from local and state governments to ensure the highest level of satisfaction for our customers. Offering a wide array of cutting edge products including fire extinguishers, exit and emergency lights, smoke detection/alarms, etc. we are your one stop shop for fire prevention and protection. Annual services for commercial properties include Fire extinguisher maintenance, smoke alarm maintenance, emergency lighting maintenance, fire alarm maintenance, sprinkler maintenance, etc. With a corporate sized workforce and mom-and-pop style customer service, we at Mako Fire Group guarantee we will meet and exceed all your expectations.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
storyoftheseason.com